Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain.

Sasaki A, Yasukawa H, Suzuki A, Kamizono S, Syoda T, Kinjyo I, Sasaki M, Johnston JA, Yoshimura A.

Genes Cells. 1999 Jun;4(6):339-51.

2.

The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop.

Yasukawa H, Misawa H, Sakamoto H, Masuhara M, Sasaki A, Wakioka T, Ohtsuka S, Imaizumi T, Matsuda T, Ihle JN, Yoshimura A.

EMBO J. 1999 Mar 1;18(5):1309-20.

3.

Cloning and characterization of novel CIS family genes.

Masuhara M, Sakamoto H, Matsumoto A, Suzuki R, Yasukawa H, Mitsui K, Wakioka T, Tanimura S, Sasaki A, Misawa H, Yokouchi M, Ohtsubo M, Yoshimura A.

Biochem Biophys Res Commun. 1997 Oct 20;239(2):439-46.

PMID:
9344848
4.

CIS3 and JAB have different regulatory roles in interleukin-6 mediated differentiation and STAT3 activation in M1 leukemia cells.

Suzuki R, Sakamoto H, Yasukawa H, Masuhara M, Wakioka T, Sasaki A, Yuge K, Komiya S, Inoue A, Yoshimura A.

Oncogene. 1998 Oct 29;17(17):2271-8.

5.

A new protein containing an SH2 domain that inhibits JAK kinases.

Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H, Miyazaki T, Leonor N, Taniguchi T, Fujita T, Kanakura Y, Komiya S, Yoshimura A.

Nature. 1997 Jun 26;387(6636):921-4.

PMID:
9202126
6.

CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2.

Sasaki A, Yasukawa H, Shouda T, Kitamura T, Dikic I, Yoshimura A.

J Biol Chem. 2000 Sep 22;275(38):29338-47.

7.

Induction of JAB/SOCS-1/SSI-1 and CIS3/SOCS-3/SSI-3 is involved in gp130 resistance in cardiovascular system in rat treated with cardiotrophin-1 in vivo.

Hamanaka I, Saito Y, Yasukawa H, Kishimoto I, Kuwahara K, Miyamoto Y, Harada M, Ogawa E, Kajiyama N, Takahashi N, Izumi T, Kawakami R, Masuda I, Yoshimura A, Nakao K.

Circ Res. 2001 Apr 13;88(7):727-32.

8.

The CIS family: negative regulators of JAK-STAT signaling.

Yoshimura A.

Cytokine Growth Factor Rev. 1998 Sep-Dec;9(3-4):197-204. Review.

PMID:
9918119
9.

A Janus kinase inhibitor, JAB, is an interferon-gamma-inducible gene and confers resistance to interferons.

Sakamoto H, Yasukawa H, Masuhara M, Tanimura S, Sasaki A, Yuge K, Ohtsubo M, Ohtsuka A, Fujita T, Ohta T, Furukawa Y, Iwase S, Yamada H, Yoshimura A.

Blood. 1998 Sep 1;92(5):1668-76.

10.

CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation.

Suzuki A, Hanada T, Mitsuyama K, Yoshida T, Kamizono S, Hoshino T, Kubo M, Yamashita A, Okabe M, Takeda K, Akira S, Matsumoto S, Toyonaga A, Sata M, Yoshimura A.

J Exp Med. 2001 Feb 19;193(4):471-81.

11.

The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation.

Iwamoto T, Senga T, Naito Y, Matsuda S, Miyake Y, Yoshimura A, Hamaguchi M.

Oncogene. 2000 Sep 28;19(41):4795-801.

12.

Cytokine-inducible SH2 protein (CIS3) and JAK2 binding protein (JAB) abolish prolactin receptor-mediated STAT5 signaling.

Helman D, Sandowski Y, Cohen Y, Matsumoto A, Yoshimura A, Merchav S, Gertler A.

FEBS Lett. 1998 Dec 18;441(2):287-91.

13.

Negative regulation of cytokine signaling pathways.

Yasukawa H, Sasaki A, Yoshimura A.

Annu Rev Immunol. 2000;18:143-64. Review.

PMID:
10837055
14.

The CIS/JAB family: novel negative regulators of JAK signaling pathways.

Yoshimura A.

Leukemia. 1998 Dec;12(12):1851-7. Review.

PMID:
9844915
15.

Interleukin-10 (IL-10) selectively enhances CIS3/SOCS3 mRNA expression in human neutrophils: evidence for an IL-10-induced pathway that is independent of STAT protein activation.

Cassatella MA, Gasperini S, Bovolenta C, Calzetti F, Vollebregt M, Scapini P, Marchi M, Suzuki R, Suzuki A, Yoshimura A.

Blood. 1999 Oct 15;94(8):2880-9.

16.

A mutant form of JAB/SOCS1 augments the cytokine-induced JAK/STAT pathway by accelerating degradation of wild-type JAB/CIS family proteins through the SOCS-box.

Hanada T, Yoshida T, Kinjyo I, Minoguchi S, Yasukawa H, Kato S, Mimata H, Nomura Y, Seki Y, Kubo M, Yoshimura A.

J Biol Chem. 2001 Nov 2;276(44):40746-54.

17.

Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling.

Narazaki M, Fujimoto M, Matsumoto T, Morita Y, Saito H, Kajita T, Yoshizaki K, Naka T, Kishimoto T.

Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13130-4.

18.

Prolactin-induced expression of cytokine-inducible SH2 signaling inhibitors in human hematopoietic progenitors.

Cwikel S, Silvian-Drachsler I, Prolov L, Hooghe-Peters EL, Merchav S.

Exp Hematol. 2001 Aug;29(8):937-42.

PMID:
11495699
19.

Identification of SH2-Bbeta as a substrate of the tyrosine kinase JAK2 involved in growth hormone signaling.

Rui L, Mathews LS, Hotta K, Gustafson TA, Carter-Su C.

Mol Cell Biol. 1997 Nov;17(11):6633-44.

20.

Differential binding to and regulation of JAK2 by the SH2 domain and N-terminal region of SH2-bbeta.

Rui L, Gunter DR, Herrington J, Carter-Su C.

Mol Cell Biol. 2000 May;20(9):3168-77.

Supplemental Content

Support Center